Structure of 161489-05-0
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
4.5
*For Research Use Only !
Change View
| Size | Price | VIP Price |
DE Stock US Stock |
Asia Stock Global Stock |
In Stock |
| {[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock Inquiry - | Login - + |
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
| CAS No. : | 161489-05-0 |
| Formula : | C5H5IN2O |
| M.W : | 236.01 |
| SMILES Code : | IC1=NC=NC(=C1)OC |
| MDL No. : | MFCD07787396 |
| InChI Key : | QDBUDQCGLQIPKI-UHFFFAOYSA-N |
| Pubchem ID : | 7127182 |
| GHS Pictogram: |
|
| Signal Word: | Warning |
| Hazard Statements: | H302-H315-H319-H332-H335 |
| Precautionary Statements: | P280-P305+P351+P338-P310 |
| Num. heavy atoms | 9 |
| Num. arom. heavy atoms | 6 |
| Fraction Csp3 | 0.2 |
| Num. rotatable bonds | 1 |
| Num. H-bond acceptors | 3.0 |
| Num. H-bond donors | 0.0 |
| Molar Refractivity | 41.24 |
| TPSA ? Topological Polar Surface Area: Calculated from |
35.01 Ų |
| Log Po/w (iLOGP)? iLOGP: in-house physics-based method implemented from |
2.0 |
| Log Po/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by |
1.19 |
| Log Po/w (WLOGP)? WLOGP: Atomistic method implemented from |
1.09 |
| Log Po/w (MLOGP)? MLOGP: Topological method implemented from |
0.69 |
| Log Po/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by |
1.89 |
| Consensus Log Po/w? Consensus Log Po/w: Average of all five predictions |
1.37 |
| Log S (ESOL):? ESOL: Topological method implemented from |
-2.48 |
| Solubility | 0.781 mg/ml ; 0.00331 mol/l |
| Class? Solubility class: Log S scale |
Soluble |
| Log S (Ali)? Ali: Topological method implemented from |
-1.52 |
| Solubility | 7.11 mg/ml ; 0.0301 mol/l |
| Class? Solubility class: Log S scale |
Very soluble |
| Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by |
-2.74 |
| Solubility | 0.432 mg/ml ; 0.00183 mol/l |
| Class? Solubility class: Log S scale |
Soluble |
| GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg |
High |
| BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg |
Yes |
| P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) |
No |
| CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) |
Yes |
| CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) |
No |
| CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) |
No |
| CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) |
No |
| CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) |
No |
| Log Kp (skin permeation)? Skin permeation: QSPR model implemented from |
-6.89 cm/s |
| Lipinski? Lipinski (Pfizer) filter: implemented from |
0.0 |
| Ghose? Ghose filter: implemented from |
None |
| Veber? Veber (GSK) filter: implemented from |
0.0 |
| Egan? Egan (Pharmacia) filter: implemented from |
0.0 |
| Muegge? Muegge (Bayer) filter: implemented from |
0.0 |
| Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat |
0.55 |
| PAINS? Pan Assay Interference Structures: implemented from |
0.0 alert |
| Brenk? Structural Alert: implemented from |
1.0 alert: heavy_metal |
| Leadlikeness? Leadlikeness: implemented from |
No; 1 violation:MW<1.0 |
| Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) |
2.31 |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

| Yield | Reaction Conditions | Operation in experiment |
|---|---|---|
| 65% | With bis-triphenylphosphine-palladium(II) chloride; copper(l) iodide; triethylamine; In tetrahydrofuran; at 20.0℃;Inert atmosphere; | General procedure: Compound 4 (1equiv per iodine atom), NEt3 (0.5mL), CuI (6mol%), and Pd(PPh3)2Cl2 (6mol%) were added to iododiazine (1mmol) in THF (5mL). The suspension was stirred at room temperature overnight under nitrogen atmosphere. The suspension was then diluted with a mixture of water and dichloromethane (1:1, 20mL) and the organic layer separated. The aqueous layer was extracted with dichloromethane (2×20mL). The combined organic extracts were dried over MgSO4, filtered, and evaporated. |
[ 161489-05-0 ]
[ 73874-95-0 ]
[ 161489-05-0 ]
| Yield | Reaction Conditions | Operation in experiment |
|---|---|---|
| 61% | With N-ethyl-N,N-diisopropylamine; In 1-methyl-pyrrolidin-2-one; at 130.0℃; for 16.0h;Inert atmosphere; | [0188] To a stirred solution of 4-iodo-6-methoxypyrimidine (500 mg, 2.12 mmol) in (0423) NMP (5 mL) was added diisopropylethylamine (383 mg, 2.96 mmol) and tert-butyl piperidin- (0424) 4-ylcarbamate (550 mg, 2.75 mmol) and purged with argon for 15 min. The reaction mixture was heated to 130 C and stirred for 16 h. After consumption of the starting materials (0425) (monitored by TLC), the mixture was diluted with ice cold water (100 mL) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by silica gel column chromatography using 10-30% EtOAc:hexanes to afford tert-butyl (l-(6-methoxypyrimidin- (0426) 4-yl) piperidin-4-yl) carbamate (400 mg, 61%) as an off-white solid. 1H-NMR (DMSO-< 5, 500 MHz): delta 8.22 (s, 1H), 6.84-6.82 (m, 1H), 6.06 (s, 1H), 4.24-4.21 (m, 2H), 3.81 (s, 3H), 3.51 (br s, 1H), 2.94 (t, 2H), 1.75-1.73 (m, 2H), 1.38 (s, 9H), 1.30-1.22 (m, 2H); LC-MS: 308.9 (M+1); (column; X-Select CSH C-18 (50 3.0 mm, 3.5 mupiiota); RT 2.45 min 0.05% Aq TFA: ACN; 0.80 mL/min); UPLC (column; Acquity BEH C-18 50 X 2.1 mm, 1.7 mupiiota); RT 1.67 min. ACN: 0.025% Aq TFA; 0.5 mL/min; TLC: 30% EtOAc:hexanes (Rf. 0.2). |
[ 847862-26-4 ]
[ 161489-05-0 ]
| Yield | Reaction Conditions | Operation in experiment |
|---|---|---|
| 85.3% | With potassium carbonate; In N,N-dimethyl-formamide; at 100.0℃;Inert atmosphere; | To a light yellow solution of tert-butyl N-[(8 endo)-3-azabicyclo[3.2.1]octan-8-yl]carbamate (250 mg, 1.1 mmol), (CAS Registry Number: 1330763-51-3), in DMF (5 ml) was added K2C03 (458 mg, 3.31 mmol) followed by 4-iodo-6-methoxypyrimidine (391 mg, 1.66 mmol). The vial was closed under argon and the reaction mixture was stirred at 100 C over night. LC-MS showed the reaction was complete. The reaction mixture was diluted with 20 mL H20 and extracted with DCM (3 x 25 mL). The organic layers were dried over MgS04 and concentrated in vacuo. The crude material was purified by flash chromatography (silica gel, 25 g, 0 % to 60 % EtOAc in heptane) to afford the title compound (315 mg, 85.3 % yield) as a white powder. MS ES+ (m/z): 335..2 [(M+H)+] |
| 85% | With potassium carbonate; In N,N-dimethyl-formamide; at 100.0℃;Sealed tube; | In analogy to the preparation of intermediate Int-54 from tert-butyl N-[(lR,5S,8s)-3- azabicyclo[3.2.1]octan-8-yl]carbamate (lnt-47, 250 mg, 1.1 mmol) and 4-iodo-6- methoxypyrimidine (lnt-56, 391 mg, 1.66 mmol) in a sealed tube at 100 C using DMF as solvent in the presence of K2C03 (458 mg, 3.31 mmol), the title compound (315 mg, 85 % yield) was obtained as a white solid. MS (ES+) m/z: 335.2 [M+H]. |
| 85% | With potassium carbonate; In N,N-dimethyl-formamide; at 100.0℃;Sealed tube; | In analogy to the preparation of the intermediate 10-1 (step 1) from tert-butyl N-[(1R,5S,8S)-3-azabicyclo[3.2.1]octan-8-yl]carbamate (250 mg, 1.1 mmol) and 4-iodo-6-methoxypyrimidine (391 mg, 1.66 mmol) in a sealed tube at 100 C using DMF as solvent in the presence of K2CO3 (458 mg, 3.31 mmol), tert-butyl N-[(1R,5S,8S)-3-(6-methoxypyrimidin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl]carbamate (315 mg, 85 % yield) was obtained as a white solid. MS (ES+) m/z 335.2 [(M+H)+]. |
[ 847862-26-4 ]
[ 161489-05-0 ]

[ 161489-05-0 ]
| Yield | Reaction Conditions | Operation in experiment |
|---|---|---|
| 66% | With copper(l) iodide; N-ethyl-N,N-diisopropylamine; In 1,2-dimethoxyethane; at 180.0℃; for 1.0h;Microwave irradiation; | Copper (I) iodide (1.013 mg, 5.32 muetaiotaomicron) was added to a mixture of 2- chloropyridine 99% (6.50 mu, 0.069 mmol), N-(4-fluoro-5-(l,2,3,6-tetrahydropyridin- 4-yl)-2-((3S,5R)-3,4,54rimethylpiperazin-1-yl)phenyl)-6-oxo-4-(trifluoromethyl)-l,6- dihydropyridine-3-carboxamide (27 mg, 0.053 mmol) and N,N-diisopropylethylamine (0.028 ml, 0.160 mmol) in ethylene glycol (1.5 ml). The mixture was heated in a microwave reactor at 180 C for lh. The mixture was quenched and worked up in a similar manner to Example 148 to provide the title compound as a yellow powder (8.5 mg, 26 %). 11H NMR (500MHz, METHANOL-d4) delta = 7.99 (dd, J=1.2, 4.9 Hz, 1H), 7.85 - 7.82 (m, 1H), 7.73 - 7.67 (m, 1H), 7.51 - 7.45 (m, 1H), 6.87 - 6.83 (m, 1H), 6.82 - 6.79 (m, 1H), 6.76 - 6.71 (m, 1H), 6.60 - 6.52 (m, 1H), 6.08 - 6.01 (m, 1H), 4.04 - 3.99 (m, 2H), 3.75 - 3.70 (m, 2H), 2.95 - 2.90 (m, 2H), 2.55 - 2.43 (m, 6H), 2.29 - 2.27 (m, 3H), 1.06 (d, J=5.9 Hz, 6H); LCMS [M+H]+ 585.5. The procedure followed was similar to Example 270 using N-(4- fluoro-5-(l,2,5,6-tetrahydropyridin-3-yl)-2-((3S,5R)-3,4,5-trimethylpiperazin-l- yl)phenyl)-6-oxo-4-(trifluoromethyl)-l,6-dihydropyridine-3-carboxamide (26 mg, 0.051 mmol) and <strong>[161489-05-0]4-Iodo-6-methoxypyrimidine</strong> (13.90 mg, 0.059 mmol) to give the title compound (22 mg, 66% yield). 11H NMR (500MHz, METHANOL-d4) delta = 8.14 - 8.06 (m, IH), 7.87 - 7.81 (m, IH), 7.72 - 7.63 (m, IH), 6.92 - 6.85 (m, IH), 6.83 - 6.77 (m, 1H),6.10 - 6.02 (m, IH), 5.96 - 5.92 (m, IH), 4.30 - 4.21 (m, 2H), 3.82 - 3.78 (m, 3H), 3.77 - 3.72 (m, 2H), 2.97 - 2.90 (m, 2H), 2.52 - 2.46 (m, 2H), 2.46 - 2.39 (m, 2H), 2.35 - 2.29 (m, 2H), 2.27 (s, 3H), 1.07 - 1.02 (m, 6H); LCMS [M+H]+ 616.6. |

[ 161489-05-0 ]
| Yield | Reaction Conditions | Operation in experiment |
|---|---|---|
| 58% | With N-ethyl-N,N-diisopropylamine; In ethanol; at 130.0℃; for 3.0h;Micellar solution; | To a microwave vial charged with N-(4-fluoro-5-(l, 2,3,6- tetrahydropyridin-4-yl)-2-((3S,5R)-3,4,5-trimethylpiperazin-1-yl)phenyl)-6-oxo-4- (trifluoromethyl)-l,6-dihydropyridine-3-carboxamide (25.5 mg, 0.050 mmol) and 4- iodo-6-methoxy pyrimidine (13.64 mg, 0.058 mmol) in ethanol (3 ml) at RT, was added N,N-diisopropylethylamine (0.018 ml, 0.100 mmol) . The mixture was heated at 130 C for 3 h. The reaction was worked up and the product was purified by sgc to afford the title compound (19 mg, 58 % yield). 1H NMR (500 MHz, METHANOL- d4) delta = 8.26 - 8.21 (m, 1H), 7.98 - 7.93 (m, 1H), 7.85 - 7.76 (m, 1H), 6.99 - 6.94 (m, 1H), 6.94 - 6.90 (m, 1H), 6.12 (br s, 1H), 6.04 (s, 1H), 4.26 - 4.16 (m, 2H), 4.00 - 3.88 (m, 5H), 3.03 (br d, J=11.0 Hz, 2H), 2.65 - 2.52 (m, 6H), 2.38 (s, 3H), 1.19 - 1.15 (m,6H); LCMS [M+H]+ 616.6 |

[ 161489-05-0 ]
| Yield | Reaction Conditions | Operation in experiment |
|---|---|---|
| 85% | With potassium carbonate; In N,N-dimethyl-formamide; at 100.0℃;Sealed tube; | In analogy to the preparation of the intermediate 8-1 (step 1) from tert-butyl N- [(lR,5S,8S)-3-azabicyclo[3.2.1]octan-8-yl]carbamate (250 mg, 1.1 mmol) and 4-iodo-6- methoxypyrimidine (391 mg, 1.66 mmol) in a sealed tube at 100 C using DMF as solvent in the presence of K2C03 (458 mg, 3.31 mmol), tert-butyl N-[(lR,5S,8S)-3-(6-methoxypyrimidin-4- yl)-3-azabicyclo[3.2.1]octan-8-yl]carbamate (315 mg, 85 % yield) was obtained as a white solid. MS (ES+) m/z: 335.2 [(M+H)+]. |
| 85% | With potassium carbonate; In N,N-dimethyl-formamide; at 100.0℃;Sealed tube; | In a sealed tube tert-butyl N-[(1R,5S,8s)-3-azabicyclo[3.2.1]octan-8-yl]carbamate (lnt-94, 500 mg, 2.21 mmol) was dissolved in EtOH (10 mL) and 4-chloro-6-methylpyrimidine (869 mg, 6.63 mmol) was added followed by triethylamine (894 mg, 1.23 mL, 8.84 mmol). The reaction mixture was stirred at 130C overnight. The crude reaction mixture was concentrated in vacuum. The residue was diluted with 20 mL of CH2Cl2 and 20 mL of water. The organic phase was extracted with CH2Cl2 (3 x 20 mL), dried over MgSO4 and concentrated in vacuum. The crude material was purified by flash chromatography (0 % to 100 % EtOAc in heptane) to afford the title compound as a yellow solid (496 mg, 71 % yield). MS (ES+) m/z: 319.2 [M+H]. In analogy to the preparation of the intermediate Int-113 from tert-butyl N-[(1R,5S,8s)-3- azabicyclo[3.2.1]octan-8-yl]carbamate (lnt-94, 250 mg, 1.1 mmol) and 4-iodo-6- methoxypyrimidine (lnt-118, 391 mg, 1.66 mmol) in a sealed tube at 100 C using DMF as solvent in the presence of K2CO3 (458 mg, 3.31 mmol), the title compound (315 mg, 85 % yield) was obtained as a white solid. MS (ES+) m/z: 335.2 [M+H]. Step 2: (lR.5S.8s)-3-(6-Methoxypyrimidin-4-yl)-3-azabicyclor3.2.11octan-8-amine (Int-120) In analogy to the preparation of intermediate Int-114 from tert-butyl N-[(1R,5S,8s)-3-(6- methoxypyrimidin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl]carbamate (lnt-119, 330 mg, 987 muiotaetaomicron) in CH2Cl2 in the presence of TFA (1.13 g, 760 mu, 9.87 mmol), the title compound (222 mg, 96 % yield) was obtained as a white solid and used directly in the next step without further purification. MS (ES+) m/z: 235.2 [M+H]. |

[ 161489-05-0 ]
| Yield | Reaction Conditions | Operation in experiment |
|---|---|---|
| 62% | With N-ethyl-N,N-diisopropylamine; In isopropyl alcohol; at 170.0℃; for 2.0h; | To a solution of(S)-4-(difluoromethyl)-N-(6-(3,4-dimethylpiperazin-1- yl)-2,4-difluoro-3 -(1,2,3 ,6-tetrahydropyridin-4-yl)phenyl)-6-oxo- 1 ,6-dihydropyridine- 3-carboxamide (31.5 mg, 0.064 mmol, preparation described in Example 34) and 2- bromo-5-methoxypyrimidine (16.89 mg, 0.089 mmol) in 2-propanol (2.5 mL) at RT was added N,N-diisopropylethylamine (0.022 ml, 0.128 mmol). After heating in a microwave reactor at 170 C for 2 h, the reaction mixture was purified on preparatory column eluting with water (containing 0.1% HCOOH)/acetonitrile (containing 0.1% HCOOH) gradient (85/55). The title compound was isolated as an yellow powder (20 mg, 50%). LCMS [M+1j 602.5. |

[ 161489-05-0 ]
| Yield | Reaction Conditions | Operation in experiment |
|---|---|---|
| 59% | With N-ethyl-N,N-diisopropylamine; In isopropyl alcohol; at 170.0℃; for 2.0h; | General procedure: To a solution of(S)-4-(difluoromethyl)-N-(6-(3,4-dimethylpiperazin-1- yl)-2,4-difluoro-3 -(1,2,3 ,6-tetrahydropyridin-4-yl)phenyl)-6-oxo- 1 ,6-dihydropyridine- 3-carboxamide (31.5 mg, 0.064 mmol, preparation described in Example 34) and 2- bromo-5-methoxypyrimidine (16.89 mg, 0.089 mmol) in 2-propanol (2.5 mL) at RT was added N,N-diisopropylethylamine (0.022 ml, 0.128 mmol). After heating in a microwave reactor at 170 C for 2 h, the reaction mixture was purified on preparatory column eluting with water (containing 0.1% HCOOH)/acetonitrile (containing 0.1% HCOOH) gradient (85/55). The title compound was isolated as an yellow powder (20 mg, 50%). LCMS [M+1j 602.5. |

[ 161489-05-0 ]
| Yield | Reaction Conditions | Operation in experiment |
|---|---|---|
| 67% | With N-ethyl-N,N-diisopropylamine; In isopropyl alcohol; at 170.0℃; for 2.0h; | General procedure: To a solution of(S)-4-(difluoromethyl)-N-(6-(3,4-dimethylpiperazin-1- yl)-2,4-difluoro-3 -(1,2,3 ,6-tetrahydropyridin-4-yl)phenyl)-6-oxo- 1 ,6-dihydropyridine- 3-carboxamide (31.5 mg, 0.064 mmol, preparation described in Example 34) and 2- bromo-5-methoxypyrimidine (16.89 mg, 0.089 mmol) in 2-propanol (2.5 mL) at RT was added N,N-diisopropylethylamine (0.022 ml, 0.128 mmol). After heating in a microwave reactor at 170 C for 2 h, the reaction mixture was purified on preparatory column eluting with water (containing 0.1% HCOOH)/acetonitrile (containing 0.1% HCOOH) gradient (85/55). The title compound was isolated as an yellow powder (20 mg, 50%). LCMS [M+1j 602.5. |

[ 161489-05-0 ]
| Yield | Reaction Conditions | Operation in experiment |
|---|---|---|
| 40% | With N-ethyl-N,N-diisopropylamine; In isopropyl alcohol; at 170.0℃; for 2.0h; | General procedure: To a solution of(S)-4-(difluoromethyl)-N-(6-(3,4-dimethylpiperazin-1- yl)-2,4-difluoro-3 -(1,2,3 ,6-tetrahydropyridin-4-yl)phenyl)-6-oxo- 1 ,6-dihydropyridine- 3-carboxamide (31.5 mg, 0.064 mmol, preparation described in Example 34) and 2- bromo-5-methoxypyrimidine (16.89 mg, 0.089 mmol) in 2-propanol (2.5 mL) at RT was added N,N-diisopropylethylamine (0.022 ml, 0.128 mmol). After heating in a microwave reactor at 170 C for 2 h, the reaction mixture was purified on preparatory column eluting with water (containing 0.1% HCOOH)/acetonitrile (containing 0.1% HCOOH) gradient (85/55). The title compound was isolated as an yellow powder (20 mg, 50%). LCMS [M+1j 602.5. |

[ 161489-05-0 ]
| Yield | Reaction Conditions | Operation in experiment |
|---|---|---|
| 25% | With N-ethyl-N,N-diisopropylamine; In isopropyl alcohol; at 170.0℃; for 2.0h; | General procedure: To a solution of(S)-4-(difluoromethyl)-N-(6-(3,4-dimethylpiperazin-1- yl)-2,4-difluoro-3 -(1,2,3 ,6-tetrahydropyridin-4-yl)phenyl)-6-oxo- 1 ,6-dihydropyridine- 3-carboxamide (31.5 mg, 0.064 mmol, preparation described in Example 34) and 2- bromo-5-methoxypyrimidine (16.89 mg, 0.089 mmol) in 2-propanol (2.5 mL) at RT was added N,N-diisopropylethylamine (0.022 ml, 0.128 mmol). After heating in a microwave reactor at 170 C for 2 h, the reaction mixture was purified on preparatory column eluting with water (containing 0.1% HCOOH)/acetonitrile (containing 0.1% HCOOH) gradient (85/55). The title compound was isolated as an yellow powder (20 mg, 50%). LCMS [M+1j 602.5. |

[ 161489-05-0 ]
| Yield | Reaction Conditions | Operation in experiment |
|---|---|---|
| 31% | With N-ethyl-N,N-diisopropylamine; In isopropyl alcohol; at 170.0℃; for 2.0h; | General procedure: To a solution of(S)-4-(difluoromethyl)-N-(6-(3,4-dimethylpiperazin-1- yl)-2,4-difluoro-3 -(1,2,3 ,6-tetrahydropyridin-4-yl)phenyl)-6-oxo- 1 ,6-dihydropyridine- 3-carboxamide (31.5 mg, 0.064 mmol, preparation described in Example 34) and 2- bromo-5-methoxypyrimidine (16.89 mg, 0.089 mmol) in 2-propanol (2.5 mL) at RT was added N,N-diisopropylethylamine (0.022 ml, 0.128 mmol). After heating in a microwave reactor at 170 C for 2 h, the reaction mixture was purified on preparatory column eluting with water (containing 0.1% HCOOH)/acetonitrile (containing 0.1% HCOOH) gradient (85/55). The title compound was isolated as an yellow powder (20 mg, 50%). LCMS [M+1j 602.5. |